Sort   by:  
 Page size 
UnknownT-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Not available
S-EPMC6075965 | biostudies-literature
GenomicsMDACC-Yale-breast-cancer
Data Access Committee EGAC00001000298
EGAC00001000298 | EGA
TranscriptomicsExpression data from breast cancer FNA biopsies from patients ( (USO samples)
Tumor samples were obtained from patients with stage II-III breast cancer before starting neoadjuvant chemotherapy with four cycles of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by four cycles of docetaxel/capecitabine (TX) on US Oncology clinical trial 02-103. Most patients with HER-...
ORGANISM(S): Homo sapiens 
2012-12-11 | E-GEOD-42822 | biostudies-arrayexpress
TranscriptomicsExpression data from paired matched breast cancer Fine needle aspiration (FNA) or Core needle biopsies (CBX)
Paired FNA and CBX specimens were prospectively collected from 37 breast cancers before any systemic therapy during a biomarker discovery study at The University of Texas M. D. Anderson Cancer Center. We identified 293 probe sets overexpressed in core biopsies; these included five highly coexpresse...
ORGANISM(S): Homo sapiens 
2011-10-31 | E-GEOD-32518 | biostudies-arrayexpress
TranscriptomicsExpression data from breast cancer FNA biopsies from patients (US samples)
This is Phase II Trial of 4courses of 5-fluorouracil, doxorubicin and cyclophosphamide follwed by 4 additional courses of weekly docetaxel and capecitabine administered as Preoperative Therapy for Patients with Locally Advanced Breast Cancer, Stages II and III by US oncology (PROTOCOL 02-103) We per...
ORGANISM(S): Homo sapiens 
2011-02-07 | E-GEOD-23988 | biostudies-arrayexpress
TranscriptomicsHER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer
We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ ...
ORGANISM(S): Homo sapiens 
2012-05-11 | E-GEOD-37946 | biostudies-arrayexpress
Genomicsena-DATASET-MDACC-Yale-15-01-2015-22:06:45:013-91 - samples
To examined the reproducibility of nucleotide variant calls in replicate sequencing experiments of the same genomic DNA, we performed targeted sequencing of all known human protein kinase genes (kinome) (~3.3 Mb) using the SOLiD v4 platform. This data set contains 17 breast cancer samples that were ...
EGAD00001001209 | EGA
GenomicsReproducibility of variant calls in replicate next generation sequencing experiments
In this study, we examined the reproducibility of nucleotide variant calls in replicate sequencing experiments of the same genomic DNA. We performed targeted sequencing of all known human protein kinase genes (kinome) (~3.3 Mb) using the SOLiD v4 platform. Seventeen breast cancer samples were sequen...
EGAS00001000826 | EGA
TranscriptomicsExpression data from breast cancer FNA biopsies from patients
We assess if distinct biological processes might be associated with chemotherapy sensitivity in the different clinical subsets of breast cancers. We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2nega...
ORGANISM(S): Homo sapiens 
2010-12-31 | E-GEOD-22093 | biostudies-arrayexpress
UnknownA Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer
Not available
ORGANISM(S): Homo sapiens 
S-ECPF-GEOD-31519 | biostudies-other
Sort   by:  
 Page size